Lupus & antiphospholipid syndrome
Hydroxychloroquine and Cardiovascular Events in Patients With Systemic Lupus Erythematosus
Main finding · Composite CV events, adjusted oddsResult — go to the resultOdds ratio 0.63 95% CI 0.57–0.69Authors' conclusion
In this nationwide cohort study of patients with SLE, a protective association was found between the current use of hydroxychloroquine and the occurrence of CV events, but not between remote use of hydroxychloroquine and CV outcomes
Study context
- Population
- All patients with systemic lupus erythematosus (SLE) recorded in the National French Healthcare Database (SNDS), 2010–20201,981 cases · 16,892 matched controls
- Participants
- 52,883 patients
- Comparison
- Current or remote hydroxychloroquine use vs no hydroxychloroquine exposure within 365 days
- Outcome
- Composite of:
- MI
- Stroke
- Other thromboembolic events (OTEs)
Methodological detailsnested case-control design, matched controls, multivariable conditional logistic regression, Controls matched on age, sex, time since SLE onset and SNDS entry, index date, prior antithrombotic and cardiovascular (CV) medication, CKD and hospitalisation
- Nested case-control design
- Matched controls
- Multivariable conditional logistic regression
- Controls matched on age, sex, time since SLE onset and SNDS entry, index date, prior antithrombotic and CV medication, CKD and hospitalisation
Main finding
Composite CV events, adjusted odds
Odds ratio
0.63
95% CI 0.57–0.69
Currentvs No exposure
OR 0.63 (95% CI 0.57–0.69)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| MICurrentvs No exposureAdjusted | 0.72 (0.60–0.85) | |
| StrokeCurrentvs No exposureAdjusted | 0.69 (0.60–0.81) | |
| Other thromboembolic events (OTEs)Currentvs No exposureAdjusted | 0.58 (0.49–0.69) | |
| 0.512Odds ratio (log scale) |
- Myocardial infarction (MI): 669 MI events
- Stroke: 916 stroke events
- Other thromboembolic events (OTEs): 696 OTEs
Original publication
Hydroxychloroquine and Cardiovascular Events in Patients With Systemic Lupus Erythematosus. JAMA Netw Open. Published 1 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →